What is Krebs Biochemicals & Industries Ltd (KREBSBIO) share price return in the past 10 years?

Krebs Biochemicals & Industries Ltd share price has declined -3.3% annually (CAGR) over the past ten years.

What is the share price of Krebs Biochemicals & Industries Ltd (KREBSBIO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Krebs Biochemicals & Industries Ltd (KREBSBIO) on 04-Jun-2026 16:59:59 at 16:59 is 65.00.

What is the P/E ratio of Krebs Biochemicals & Industries?

The latest standalone P/E ratio of Krebs Biochemicals & Industries as of 04-Jun-2026 is 0.00.

What is the P/B ratio of Krebs Biochemicals & Industries Ltd (KREBSBIO)?

The latest standalone P/B ratio of Krebs Biochemicals & Industries Ltd (KREBSBIO) as of 04-Jun-2026 is -0.86.

What is the 52-week high and low of Krebs Biochemicals & Industries Ltd (KREBSBIO)?

The 52-week high of Krebs Biochemicals & Industries Ltd (KREBSBIO) is Rs. 113.90 and the 52-week low is Rs. 38.52.

Krebs Biochemicals & Industries Ltd (KREBSBIO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Krebs Biochemicals & Industries Ltd (KREBSBIO)
Brand: Krebs Biochemicals & Industries

Krebs Biochemicals & Industries Ltd (KREBSBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524518 NSE: KREBSBIO Pharmaceuticals & Drugs | Small Cap | Krebs Biochem.&Inds Share Price

Krebs Biochemicals & Industries Ltd (KREBSBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524518 NSE: KREBSBIO Pharmaceuticals & Drugs | Small Cap | Krebs Biochem.&Inds Share Price

Key Metrics

Valuation Multiples

Market Cap

₹140 Cr.

Current Price

₹65

52-Week Low / High

₹39 / 114

TTM EPS

₹-7.9

TTM Sales

₹23.7 Cr.

Book Value per Share

₹-75.7

P/E Ratio

0.00

Industry PE

46.5

Price to Book (P/B)

-0.86

Higher than its 5-year historical median

Price to Sales (P/S)

5.91

Higher than its 5-year historical median

EV/EBITDA

-106.59

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.00%

Underperforms industry median

Return on Capital Employed (ROCE)

-29.92%

Underperforms industry median

Return on Assets (ROA)

-15.52%

Operating Profit Margin

-34.7%

Net Profit Margin

-62.2%

Gross Profit Margin

-46.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-14.1%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

72.74%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹-185 Cr.

Equity

₹21.6 Cr.

Face Value

₹10

All Time Low / High

₹9.10 / 293.59

Krebs Biochemicals & Industries stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Krebs Biochemicals & Industries Ltd a good quality company?

Krebs Biochemicals & Industries Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Krebs Biochemicals & Industries Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Krebs Biochemicals & Industries Ltd vs industry peers?

Krebs Biochemicals & Industries Ltd revenue CAGR is 5.33%, compared to the industry median CAGR of 5.35%, indicating stable growth and maintaining its market share.

Q.1 Promoter shareholding and pledge status of Krebs Biochemicals & Industries Ltd?

Promoters hold 72.74% of the Krebs Biochemicals & Industries Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Krebs Biochemicals & Industries Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -5.7% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-25.4%	-27.1%	-29%	-35.4%	-57%	-40.3%	-57.4%	-28.6%	-19%	-29.9%	-
Value Creation Index ⓘ	-2.8	-2.9	NA	NA	NA	NA	NA	NA	NA	NA	-
Growth Parameters ⓘ
Sales ⓘ	1.3	3.5	33.8	47.8	33.4	53.7	59.7	52.1	50.4	43.3	24
Sales YoY Gr.	-	173.6%	856.9%	41.4%	-30.1%	60.7%	11.2%	-12.7%	-3.3%	-14.1%	-
Adj EPS ⓘ	-12.9	-11.4	-12.4	-12.1	-16	-14.5	-20.7	-11.5	-9.2	-12.5	-7.9
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	6.9	1	-12.5	-8.6	-18.1	-23.9	-34.8	-46.1	-55.3	-67.8	-75.7
Adj Net Profit ⓘ	-17.4	-16.2	-17.6	-20.1	-28.9	-28.4	-44.5	-24.7	-19.7	-27	-17
Cash Flow from Ops. ⓘ	-15.3	-11.2	-6.2	3.9	-35.5	-14.6	-17.2	-24.7	2.4	-7.9	-
Debt/CF from Ops. ⓘ	-2	-4.2	-9.1	13.7	-1.9	-7.6	-8.3	-7.4	81.9	-26.9	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	47.8%	5.3%	-10.2%	-14.1%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-228.9%	NA	NA	NA
Share Price	-3.3%	-12%	0.3%	-18.8%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-111.2	-224.2	216.4	125.3	147	83.7	75.6	28.3	18	20.4	10.9
Op. Profit Mgn % ⓘ	-961.7	-226.6	-22.2	-20.4	-55.5	-32.7	-56.9	-30.3	-17.3	-34.7	-23
Net Profit Mgn % ⓘ	-1349.5	-460.1	-52.2	-42.1	-86.4	-52.8	-74.6	-47.4	-39.1	-62.4	-71.3
Debt to Equity ⓘ	3.3	32.2	-3.2	-3.7	-2	-2.4	-1.9	-1.8	-1.6	-1.5	-
Working Cap Days ⓘ	7,106	1,488	201	158	243	179	218	231	179	195	117
Cash Conv. Cycle ⓘ	1,149	366	-17	-32	-1	1	21	0	-11	-36	-1,204

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	1	4	34	48	33	54	60	52	50	43
Operating Expenses ⓘ +	14	12	41	58	52	71	94	68	59	58
Manufacturing Costs	4	2	13	16	17	26	33	23	33	33
Material Costs	0	1	13	23	16	26	41	26	7	6
Employee Cost	6	6	11	14	15	15	15	16	16	16
Other Costs ⓘ	3	3	4	4	4	4	5	3	3	3
Operating Profit ⓘ	-12	-8	-8	-10	-19	-18	-34	-16	-9	-15
Operating Profit Margin (%)	-961.0%	-226.0%	-22.2%	-20.4%	-55.5%	-32.7%	-56.9%	-30.3%	-17.3%	-34.7%
Other Income ⓘ +	1	0	0	0	0	1	1	1	0	1
Exceptional Items ⓘ	0	-0	-1	0	0	0	0	0	0	0
Interest ⓘ	1	3	5	6	6	6	5	3	5	6
Depreciation ⓘ	4	4	4	4	5	5	6	7	7	7
Profit Before Tax ⓘ	-16	-16	-18	-20	-29	-28	-45	-25	-20	-27
Tax ⓘ	0	0	0	0	0	0	0	0	0	0
Profit After Tax	-16	-16	-18	-20	-29	-28	-45	-25	-20	-27
PAT Margin (%)	-1,265.6%	-454.0%	-52.8%	-41.9%	-86.4%	-52.8%	-74.6%	-47.4%	-39.1%	-62.2%
Adjusted EPS (₹)	-12.1	-11.3	-12.5	-12.0	-16.0	-14.5	-20.7	-11.5	-9.2	-12.5
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Krebs Biochem.&Inds - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	9	1	-18	-14	-33	-47	-75	-99	-119	-146
Share Capital ⓘ	13	14	14	17	18	20	22	22	22	22
Reserves ⓘ	-4	-12	-32	-31	-51	-67	-97	-121	-141	-168
Debt +	25	43	52	50	66	111	143	183	193	212
Long Term Debt	25	43	52	50	66	101	133	173	184	161
Short Term Debt	0	0	0	0	0	10	10	10	10	51
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	12	11	18	21	23	21	38	15	19	18
Others Liabilities ⓘ	69	67	74	85	78	75	84	76	85	85
Total Liabilities ⓘ	116	122	126	142	134	159	190	175	178	169
Fixed Assets
Net Fixed Assets ⓘ +	93	102	101	101	105	118	139	147	150	146
Gross Block	213	227	230	234	243	261	288	303	312	314
Accumulated Depreciation	120	124	129	133	138	143	149	156	163	168
CWIP ⓘ	11	4	4	3	4	12	8	4	2	3
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	6	5	12	9	15	17	26	12	10	6
Trade Receivables	0	2	0	3	0	0	1	1	2	0
Cash Equivalents	0	0	0	17	0	1	0	0	0	0
Others Assets ⓘ	7	9	9	8	9	12	16	11	14	14
Total Assets ⓘ	116	122	126	142	134	159	190	175	178	169

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-15	-11	-6	4	-35	-15	-17	-25	2	-8
PBT ⓘ	-17	-16	-17	-20	-29	-28	-45	-25	-20	-27
Adjustment ⓘ	3	11	6	10	9	12	11	10	12	12
Changes in Working Capital ⓘ	-1	-2	9	14	-16	2	16	-10	10	7
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	-0
Cash Flow From Investing Activity ⓘ +	-4	-5	-3	-4	-10	-23	-23	-13	-8	-5
Capex	4	-13	-4	-5	-9	-18	-27	-15	-9	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-8	9	2	1	-2	-5	4	3	2	-5
Cash Flow From Financing Activity ⓘ +	13	16	9	17	29	38	40	37	6	13
Net Proceeds from Shares ⓘ	19	4	0	25	19	10	13	0	0	0
Net Proceeds from Borrowing ⓘ	8	17	9	-2	15	33	0	0	10	-22
Interest Paid ⓘ	0	0	0	-6	-6	-6	-5	-3	-5	-6
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-14	-5	0	1	0	-0	32	40	-0	41
Net Cash Flow ⓘ	-6	-0	0	17	-17	1	-1	-0	0	0

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-683.34	-296.7	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROCE (%)	-25.38	-27.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover Ratio	0.01	0.03	0.27	0.36	0.24	0.37	0.34	0.29	0.29	0.25
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	51.90	83.60	10.30	12.40	17	1.70	3.60	4.90	8.80	8.20
Inventory Days	1,435.60	573.30	92.80	79.10	130.90	107.40	128.90	131.30	78.70	66.70
Payable Days	0	3,558.80	413.90	309.60	507.30	305.40	263.50	378	948.90	1,219.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Krebs Biochemicals & Industries Ltd FAQs

The current trading price of Krebs Biochem.&Inds on 04-Jun-2026 16:59 is ₹65.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Krebs Biochem.&Inds stood at ₹140.1 Cr

The latest P/E ratio of Krebs Biochem.&Inds as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Krebs Biochem.&Inds as of 03-Jun-2026 is -0.86.

The 52-week high of Krebs Biochem.&Inds is ₹113.9 and the 52-week low is ₹38.52.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Krebs Biochem.&Inds is ₹23.73 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Krebs Biochemicals & Industries Ltd is a below average quality company.

The key valuation ratios of Krebs Biochemicals & Industries Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Krebs Biochemicals & Industries Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.

KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.

KBILâ€™s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.

The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.

KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).

Product range of the company includes:

Bulk activities

Synthetic

Lavastatin
Simvastatin
I -Ephedrochiloride
l - Ephedrine Sulphate
l - Ephedrine Base (Liquid)
d - Pseudoephedrine Hydrochloride
d - Pseudoephedrine Sulphate
d - Pseudoephedrine Base
dl - Ephedrine Base
n - Methyl Ephedrine
d - Ephedrine Bitartarate
Vitamin C
Vitamin C (Coated)

Herbal

Calcium Sennosides - 20% & 60%
Garcinia Combogia Powdered Extract
Capsaicin - 50/100

Intermediates

Crude Lovastatin
Simvastatin Ammonium Salt

Products in pipeline

Pravastatin Sodium

Achievements/ recognition:

ISO 9002 in November 2001
EDQM July 2003
USFDA in November 2003
ISO 9001 â€“ 2000 in March 2004
WHO GMP certification in November 2002 and renewed in March 2005

Krebs Biochemicals & Industries Ltd (KREBSBIO)

Krebs Biochemicals & Industries Ltd (KREBSBIO)

Krebs Biochemicals & Industries stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Krebs Biochem.&Inds - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Krebs Biochemicals & Industries Ltd FAQs

About Krebs Biochemicals & Industries Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Krebs Biochemicals & Industries Ltd (KREBSBIO)

Krebs Biochemicals & Industries Ltd (KREBSBIO)

Krebs Biochemicals & Industries stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Krebs Biochem.&Inds - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Krebs Biochemicals & Industries Ltd FAQs

What is the share price of Krebs Biochem.&Inds?

What is the market cap of Krebs Biochem.&Inds?

What is the P/E ratio of Krebs Biochem.&Inds?

What is the P/B ratio of Krebs Biochem.&Inds?

What is the 52-week high and low of Krebs Biochem.&Inds?

What is the TTM revenue of Krebs Biochem.&Inds?

Is Krebs Biochemicals & Industries Ltd a good quality company?

Is Krebs Biochemicals & Industries Ltd undervalued or overvalued?

Is Krebs Biochemicals & Industries Ltd a good buy now?

About Krebs Biochemicals & Industries Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.